Skip to main
ZVRA
ZVRA logo

ZVRA Stock Forecast & Price Target

ZVRA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zevra Therapeutics Inc. has demonstrated strong market traction following the launch of its therapy MIPLYFFA, reflected by $10.1 million in sales during the first quarter, significantly surpassing initial estimates. The company exhibits a robust growth trajectory with an increasing number of patient enrollments—109 TRx forms received as of December 31, 2024—indicative of strong demand and effective outreach strategies. Additionally, as awareness campaigns develop and the company expands its market reach, particularly in the European market with an estimated 1,100 Niemann-Pick type C patients, the outlook for 2025 sales remains highly optimistic.

Bears say

Zevra Therapeutics is facing significant financial challenges, as reflected by a GAAP net income loss of $20.4 million and a substantial 4Q net loss of $35.7 million, indicating ongoing struggles for profitability. Compounding these issues are concerns regarding poor payer coverage and recent competitor approvals, which could negatively impact drug sales and market penetration for their offerings, including Miplyffa and Olpruva. Additionally, the company's pipeline holds risks of failure in clinical stages, limiting future development options and further depressing investor interest amidst a history of sustained losses.

ZVRA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zevra Therapeutics Inc (ZVRA) Forecast

Analysts have given ZVRA a Strong Buy based on their latest research and market trends.

According to 8 analysts, ZVRA has a Strong Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zevra Therapeutics Inc (ZVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.